

CANNTAB PRODUCTS TO LAUNCH IN AUSTRALIA

Cann Global Limited (ASX: CGB) (Cann Global or the Company) is pleased to announce the launch in Australia of the company's unique formulation of medical Cannabis tablets via its joint-venture partnership with Canntab Therapeutics Limited ("Canntab Therapeutics (CSE:PILL.CN) (OTCQB:CTABF) (FRA:TBF1.F)").

Cann Global entered into a 50/50 Joint Venture with Canntab Therapeutics in January 2018 to bring their suite of hard pill cannabinoid formulations to Australia. For details on the Canntab products and the JV, please see the announcement made by the company at the time on the ASX:

<https://www.asx.com.au/asx/statistics/displayAnnouncement.do?display=pdf&idsId=01939872>

Canntab Therapeutics manufactures and distributes a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. Canntab Therapeutics is already the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications in Canada.

Cann Global is pleased to confirm the import permit has been received and an initial order for these products has been made in order to release the products into the Australian market for the first time. Cann Global is importing 6 products out of the Canntab range for distribution to the Australian market. The range CGB is importing contains two THC products, two CBD only and two THC/CBD blends. The CBD products could also benefit from the TGA's proposed amendment to create a new Schedule 3 entry for cannabidiol (CBD) which will allow greater access to CBD products. The TGA released a notice of interim decision to amend the Poisons Standard for CBD on 9th September 2020. This amendment would allow Australian patients to purchase CBD products upon consultation with a pharmacist, without the need for a prescription. The TGA has announced 1 June 2021 as the proposed implementation date.

In Australia, the current path to patients is through the Special Access Scheme B (SAS-B) and Authorised prescriber schemes. Medcan holds a QLD wholesaling licence allowing distribution of Medicinal Cannabis products Australia wide and has a QLD Health and ODC approved facility with dedicated secure storage and dispatch capabilities. Medcan also has approved freight partners allowing Australia wide logistics, access to various networks of prescribing doctors and pharmacies Australia wide and an online purchasing portal allowing seamless transactions for pharmacies.

Cann Global is also pleased to announce it has entered into a Grant Agreement with Applied Cannabis Research ("ACR") to provide a grant to ACR to support the Cannabinoid Medicine Observational Study ("CMOS") on the hard pill cannabinoid formulations produced by Canntab. This is the largest observational study ever undertaken in Australia for Cannabinoid Medicine products. CMOS will collect data from 20,000 patients nationwide to assess the safety and efficacy of medicinal cannabis products.

ASX ANNOUNCEMENT

26 OCTOBER 2020



Cann Global will supply these products through its joint venture with Canntab to the CMOS Study with the aim to collect data about health-related outcomes from patients prescribed with these products.

Unlike clinical trials, an observational study only requires a very small investment and the company will receive revenue when a patient participating in the study purchases the CannTab product as prescribed by a Medical Practitioner.

Participation in this CMOS will provide early exposure of the product in Australia to both medical practitioners and patients. CMOS provides a first-of-its-kind opportunity to capture data from a broader range of Australian prescribers and patients than in existing studies.

Sholom Feldman, CGB's Managing Director says: "We are very excited to progress the launch of CannTab's innovative cannabis-based tablets in Australia which we expect will be very sought-after by Doctors who are looking to prescribe pharmaceutical grade medicinal Cannabis products to their patients. It is our understanding from discussions with medical professionals that it is easier for them to prescribe a uniform dosage tablet produced to pharmaceutical grade standards compared to unreliability of delivery methods used by other products already on the market, giving our product a solid competitive advantage."

A handwritten signature in black ink, appearing to read "Pnina Feldman".

PNINA FELDMAN
Executive Chair

ABOUT CANN GLOBAL

Cann Global Limited (ASX:CGB) is a driving force in the hemp and medical Cannabis industries. Our strength comes from our team's core competencies and expertise, and our solid and strategic partnerships with experts in Australia, USA, Israel, Asia, Africa and Canada. We are working under the relevant legislation to ensure that the future in medical Cannabis and Natural Foods will allow medical practitioners, patients, and consumers to gain access to the right information, as well as the safest, most effective and sustainable products.

AUTHORITY AND CONTACT DETAILS

This announcement has been authorised for release by Sholom D. Feldman, Managing Director. For further information please contact Sholom Feldman, Managing Director, on +61 (0)2 8379 1832, or via email sfeldman@cannglobal.com.au